NIH-Funding

NIH-CASIS Coordinated Microphysiological Systems Program for Translational Research in Space (UG3/UH3) (Clinical Trials Not Allowed)

NIH Funding Announcements - Thu, 11/30/2017 - 02:40
Funding Opportunity RFA-TR-18-001 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to promote the development of in vitro microphysiological systems in modeling human diseases and conditions that mimic the pathology in major organs and tissues in the human body, when exposed to the extreme environments of space, and the use of these models at the International Space Station-U.S. National Laboratory (ISS-NL) to facilitate the assessment of biomarkers, bioavailability, efficacy, and toxicity of therapeutic agents prior to entry into clinical trials. Funds from the NIH will be made available through the UG3/UH3 cooperative agreement mechanism. During the initial two-year UG3 phase, support will be provided to develop robust models that recapitulate the progression and pathology of human diseases and conditions exposed to prolonged microgravity environment. Following administrative review, the two-year UH3 phase will build upon successful UG3 models to demonstrate the functional utility of the models for more defined experiments at the ISS-NL. It is anticipated that these studies will lead to identification of novel treatment mechanisms through better understanding of disease biology, drug screening, assessment of candidate therapies for efficacy and safety assessments, and establishing the pre-clinical foundation that will inform clinical trial design on Earth.
Categories: NIH-Funding

Notice of Correction to Key Dates for PAR-18-020 "NCI Clinical and Translational Exploratory/Developmental Studies (R21)"

NIH Funding Announcements - Thu, 11/30/2017 - 02:28
Notice NOT-CA-18-023 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

NIBIB Research Project Grant (R01 Clinical Trial Required)

NIH Funding Announcements - Thu, 11/30/2017 - 02:00
Funding Opportunity PA-18-418 from the NIH Guide for Grants and Contracts. The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This NIBIB Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of the NIBIB.
Categories: NIH-Funding

NIDDK Mentored Research Scientist Development Award (K01-No Independent Clinical Trials)

NIH Funding Announcements - Wed, 11/29/2017 - 13:34
Funding Opportunity PAR-18-419 from the NIH Guide for Grants and Contracts. The purpose of the NIDDK Mentored Research Scientist Development Award (K01) is to provide support and protected time (three, four, or five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. The NIDDK invites K01 applications from experienced postdoctoral (two years minimum) and/or recently appointed junior faculty (usually with a Ph.D. degree) in biomedical or behavioral sciences who are pursuing careers in research areas supported by the NIDDK. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial that is itself comprised of a clinical trial intervention(s). Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor . Applicants proposing a clinical trial or an ancillary study (that is itself a clinical trial) to an ongoing clinical trial as lead investigator, should apply to the companion FOA (PAR-DK-18-NNN).
Categories: NIH-Funding

NIDDK Mentored Research Scientist Development Award (K01-Clinical Trial Required)

NIH Funding Announcements - Wed, 11/29/2017 - 13:33
Funding Opportunity PAR-18-418 from the NIH Guide for Grants and Contracts. The purpose of the NIDDK Mentored Research Scientist Development Award (K01) is to provide support and protected time for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. The NIDDK invites K01 applications from experienced postdoctoral (two years minimum) and/or recently appointed junior faculty (usually with a Ph.D. degree) in biomedical, behavioral, or clinical sciences who are pursuing careers in research areas supported by the NIDDK. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. The ancillary study must also meet the NIH clinical trial definition. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-18-NNN).
Categories: NIH-Funding

Health Services Research on Minority Health and Health Disparities (R21 Clinical Trial Optional)

NIH Funding Announcements - Wed, 11/29/2017 - 12:57
Funding Opportunity PAR-18-287 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage innovative exploratory and developmental health services research to improve minority health and/or reduce health disparities at the health care system-level as well as within clinical settings.
Categories: NIH-Funding

Health Services Research on Minority Health and Health Disparities (R01 Clinical Trial Optional)

NIH Funding Announcements - Wed, 11/29/2017 - 12:55
Funding Opportunity PAR-18-286 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage innovative health services research that can directly and demonstrably contribute to the improvement of minority health and/or the reduction of health disparities at the health care system-level as well as within clinical settings.
Categories: NIH-Funding

Limited Competition: Centers of Biomedical Research Excellence (COBRE) Phase III - Transitional Centers (P30 Clinical Trial Optional)

NIH Funding Announcements - Wed, 11/29/2017 - 12:53
Funding Opportunity PAR-18-263 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to transition the core resources and biomedical research activities of Centers of Biomedical Research Excellence (COBRE) into independence and sustainability.
Categories: NIH-Funding

Quantitative Imaging Tools and Methods for Cancer Response Assessment (U01 Clinical Trial Optional)

NIH Funding Announcements - Wed, 11/29/2017 - 12:40
Funding Opportunity PAR-18-249 from the NIH Guide for Grants and Contracts. This purpose of this Funding Opportunity Announcement (FOA) is to provide a mechanism of support to research organizations interested in clinically translating already optimized quantitative imaging software tools capable of measuring or predicting the response of cancer to clinical therapies, or in translating imaging tools for planning and validating radiation therapy treatment strategies in clinical trials. The quantitative tools must have been developed and optimized during a performance period in the Quantitative Imaging Network (QIN) or under other separate funding. The proposed research effort should be an extension of the research that successfully completed the tasks of developing and optimizing the chosen software tools or data collection methods intended to facilitate clinical decision making during clinical trials. This FOA is intended to support the efforts of validating those tools in prospective multisite clinical trials in order to test tool performance and to demonstrate that the tool can be integrated into clinical workflow with a minimum of disruption.
Categories: NIH-Funding

Quantitative Imaging Tools and Methods for Cancer Therapy Response Assessment (UG3/UH3 Clinical Trial Optional)

NIH Funding Announcements - Wed, 11/29/2017 - 12:37
Funding Opportunity PAR-18-248 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages research project applications under the cooperative agreement (UG3/UH3) mechanism to address the development, optimization and validation of quantitative imaging (QI) software tools and methods for prediction and/or measurement of response to cancer therapies or for planning and validating radiation therapy treatment strategies in clinical trials.
Categories: NIH-Funding

Strengthening the HIV Pre-Exposure Prophylaxis (PrEP) Care Continuum through Behavioral, Social, and Implementation Science (R01 Clinical Trial Optional)

NIH Funding Announcements - Wed, 11/29/2017 - 12:35
Funding Opportunity PA-18-281 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits behavioral, social, and implementation science research designed to (a) identify gaps in the HIV pre-exposure prophylaxis (PrEP) care continuum and associated determinants; (b) develop and test interventions to strengthen PrEP delivery, use, and outcomes; and (c) reduce racial/ethnic and age-related disparities in PrEP uptake and use.
Categories: NIH-Funding

Targeted Implementation Science to Achieve 90/90/90 Goals for HIV/AIDS Prevention and Treatment (R21 Clinical Trial Optional)

NIH Funding Announcements - Wed, 11/29/2017 - 12:21
Funding Opportunity PA-18-280 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages implementation research projects designed in partnership with global and domestic service providers, to target the particular needs in the selected community, to achieve the 90/90/90 HIV prevention and treatment targets identified by HIV/AIDS global leadership. The targets for HIV testing are that 90% of all persons living with HIV know their status, for treatment initiation that 90% of those diagnosed receive timely and effective antiretroviral treatment (ART), and for optimal treatment and preventive benefit that 90% of those on treatment achieve sustained viral suppression.
Categories: NIH-Funding

Targeted Implementation Science to Achieve 90/90/90 Goals for HIV/AIDS Prevention and Treatment (R01 Clinical Trial Optional)

NIH Funding Announcements - Wed, 11/29/2017 - 12:19
Funding Opportunity PA-18-279 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages implementation research projects designed in partnership with global and domestic service providers, to target the particular needs in the selected community, to achieve the 90/90/90 HIV prevention and treatment targets identified by HIV/AIDS global leadership. The targets for HIV testing are that 90% of all persons living with HIV know their status, for treatment initiation that 90% of those diagnosed receive timely and effective antiretroviral treatment (ART), and for optimal treatment and preventive benefit that 90% of those on treatment achieve sustained viral suppression.
Categories: NIH-Funding

NIA Intervention Testing Program (ITP) Announces Annual Call for Compounds to Test for Anti-Aging Activity in Mice

NIH Funding Announcements - Wed, 11/29/2017 - 12:15
Notice NOT-AG-17-019 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Notice of Intent to Publish a Funding Opportunity Announcement for Genetics of Tolerance (R01- Clinical Trial Not Allowed)

NIH Funding Announcements - Wed, 11/29/2017 - 12:10
Notice NOT-AA-17-016 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Innovations in HIV Testing, Adherence, and Retention to Optimize HIV Care Continuum Outcomes (R01 Clinical Trial Optional)

NIH Funding Announcements - Wed, 11/29/2017 - 12:06
Funding Opportunity PA-18-278 from the NIH Guide for Grants and Contracts. The health and preventive benefits of treatment for HIV/AIDS, regardless of CD4 count, are now unequivocal. In the United States and globally, ambitious goals have been targeted for HIV testing, adherence, and retention in care, to optimize HIV clinical outcomes and preventive benefit. Additional tools are needed to inform the gaps and strategies that are unique to particular populations, cities, regions, and countries. Applications appropriate for this FOA could include formative basic behavioral and social science to better understand a step in the care continuum and/or multiple steps in the HIV care continuum, initial development and pilot tests of innovative approaches for intervention, and intervention efficacy trials.
Categories: NIH-Funding

Innovations in HIV Testing, Adherence, and Retention to Optimize HIV Care Continuum Outcomes (R21 Clinical Trial Optional)

NIH Funding Announcements - Wed, 11/29/2017 - 12:04
Funding Opportunity PA-18-277 from the NIH Guide for Grants and Contracts. The health and preventive benefits of treatment for HIV/AIDS, regardless of CD4 count, are now unequivocal. In the United States and globally, ambitious goals have been targeted for HIV testing, adherence, and retention in care, to optimize HIV clinical outcomes and preventive benefit. Additional tools are needed to inform the gaps and strategies that are unique to particular populations, cities, regions, and countries. Applications appropriate for this FOA could include formative basic behavioral and social science to better understand a step in the care continuum and/or multiple steps in the HIV care continuum, and initial development and pilot tests of innovative approaches for intervention.
Categories: NIH-Funding